Answers are grounded in this paper and cite their sources.
Camptothecin (CPT)-derived anticancer agents stabilize topoisomerase I (TOP1)−DNA cleavage complexes (TOP1ccs), but their therapeutic utility is constrained by lactone instability, variable pharmacokinetics, and systemic toxicity. This Perspective evaluates prodrug strategies according to their initiating activation mechanisms, distinguishing self-immolative chemistry as a payload-release module. Small-molecule prodrugs are emphasized, alongside peptide−drug conjugates, antibody−drug conjugates, polymeric prodrugs, and nanoprodrugs. We propose an exposure-first, “design backward, validate forward” framework in which intended tumor exposure to active lactone and TOP1cc formation guide the payload selection, attachment site, activation compartment, linker kinetics, and delivery platform. Translational evaluation should establish colocalization of intact prodrug and accessible activating stimulus, faithful release of the intended payload, and a favorable balance between tumor exposure and exposure in dose-limiting normal tissues. Additional platform complexity should yield measurable pharmacological benefits. This framework provides practical criteria for prioritizing CPT prodrugs with the potential to improve the therapeutic index.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: